These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 540075)

  • 21. [Trial of nicergoline in arteriopathies of the lower limbs (apropos of 33 cases)].
    Debaert M; Ribet M; Quandalle P
    Lille Med; 1981 Mar; 26(3):140-3. PubMed ID: 7289750
    [No Abstract]   [Full Text] [Related]  

  • 22. [From ergot alkaloids to nicergoline/Chemical points of view (author's transl)].
    Bernardi L
    Arzneimittelforschung; 1979; 29(8a):1204-6. PubMed ID: 540064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Use of nicergoline (Sermion) in the treatment of migraine].
    Prusiński A; Durko A; Selmaj K
    Wiad Lek; 1984 Mar; 37(6):420-2. PubMed ID: 6385484
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of arterial hypertension in the elderly with an alpha-blocker: nicergoline (author's transl)].
    Forette F; Varin D; Henry JF; Hervy MP
    Nouv Presse Med; 1980 Dec; 9(48):3685-8. PubMed ID: 7005872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Action of Nicergoline (Sermion) in chronic vascular disease in old age].
    Michelangeli J; Sevilla M; Lavagna J; Darcourt G
    Ann Med Psychol (Paris); 1975 Apr; 1(4):499-510. PubMed ID: 788599
    [No Abstract]   [Full Text] [Related]  

  • 26. [Sermion treatment of middle-aged and elderly patients with initial atherosclerotic encephalopathy].
    Man'kovskiĭ NB; Mints AIa; Bachinskaia NIu; Kochubeĭ NV
    Vrach Delo; 1989 Apr; (4):60-3. PubMed ID: 2756691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of nicergoline on the intellectual performance (author's transl)].
    Donoso A; Santander M; Sarce H
    Rev Med Chil; 1979 Sep; 107(9):817-9. PubMed ID: 396627
    [No Abstract]   [Full Text] [Related]  

  • 28. [Hemodynamic effects of nicergolin in man at rest and during exertion (author's transl)].
    Boismare F; Lefrançois J
    Arzneimittelforschung; 1979; 29(8a):1261-6. PubMed ID: 540069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Controlled study with nicergoline and placebo in cerebral and peripheral vascular insufficiency in the aged].
    Cascone A; Liverta C; Pollini C
    Minerva Cardioangiol; 1978; 26(1-2):95-100. PubMed ID: 347330
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical and biochemical effects of nicergoline in chronic schizophrenic patients.
    Albus M; Botschev C; Müller-Spahn F; Naber D; Münch U; Ackenheil M
    Pharmacopsychiatry; 1986 May; 19(3):101-5. PubMed ID: 3725889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of some of the pharmacological properties of the new eburnamenine derivative vindeburnol with those of vincamine, vinburnine, dihydroergotoxine mesilate and nicergoline.
    Barzaghi F; Dragonetti M; Formento ML; Gueniau C; Nencioni A; Mantegazza P
    Arzneimittelforschung; 1986 Oct; 36(10):1442-8. PubMed ID: 3814205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Nicergoline and cerebral performance insufficiency. Observations in 1 year treatment controls].
    Kugler J; Heidrich H
    Fortschr Med; 1984 Nov; 102(42):1091-6. PubMed ID: 6392047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cerebrovascular disorders : facial thermography as a means to evaluate the therapeutic effectiveness of nicergoline].
    Sbarbaro V; Zardini GB; Morgante R; Mora L; Acciarri L; Pistolesi GF
    Farmaco Prat; 1976 Nov; 31(11):549-60. PubMed ID: 1017468
    [No Abstract]   [Full Text] [Related]  

  • 34. [Use of sermion in cerebral atherosclerosis patients with a history of ischemic stroke].
    Tsimenko OA; Sosnov IuD; Kharchenko AP; Gaĭduk IuS
    Vrach Delo; 1988 Jul; (7):24-7. PubMed ID: 3188456
    [No Abstract]   [Full Text] [Related]  

  • 35. [Importance of improving sympathetic tonus in the medical treatment of impotence with vascular disorders: clinical and ultrasonic study of the action of nicergoline].
    Chomant J; de Somer-Leroy R; Boismare F; Boquet J; Ozenne G; Schrub JC
    LARC Med; 1982 Sep; 2(8):717-9. PubMed ID: 7162273
    [No Abstract]   [Full Text] [Related]  

  • 36. [The effect of sermion on the main hemodynamic indices in patients with the initial manifestations of cerebral atherosclerosis].
    Tokar' AV; Akhaladze NG; Ena LM; Rudaia ES; Severova NL
    Vrach Delo; 1990 Feb; (2):27-30. PubMed ID: 2339544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of the effectiveness and tolerance of the preparation Sermion in the treatment of selected retinal diseases].
    Szaflik J; Jupowiecka A
    Klin Oczna; 1985 Apr; 87(4):165-6. PubMed ID: 3900547
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical study of injectable sermion in otologic diseases].
    Gaillard J; Dubreuil C
    J Fr Otorhinolaryngol Audiophonol Chir Maxillofac; 1979 Sep; 28(7):477-80. PubMed ID: 41025
    [No Abstract]   [Full Text] [Related]  

  • 39. [Results of the double-blind use of an alpha blockader, nicergoline, in cervico-prostatic dysfunctions].
    Colombeau P; Ballanger P
    J Urol (Paris); 1987; 93(9-10):533-5. PubMed ID: 3327892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Nicergoline to reduce intraoperative blood pressure increases in hypertensive patients].
    Muchada R; Lavandier B; Cathignol D; Lamazou J; Haro D; Lucchesi G; Roux MJ
    Cah Anesthesiol; 1985 Nov; 33(7):593-8. PubMed ID: 4092160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.